GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » China Shineway Pharmaceutical Group Ltd (OTCPK:CSWYY) » Definitions » Debt-to-Revenue

CSWYY (China Shineway Pharmaceutical Group) Debt-to-Revenue : 0.08 (As of Jun. 2024)


View and export this data going back to 2008. Start your Free Trial

What is China Shineway Pharmaceutical Group Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

China Shineway Pharmaceutical Group's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was $46.7 Mil. China Shineway Pharmaceutical Group's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was $1.7 Mil. China Shineway Pharmaceutical Group's annualized Revenue for the quarter that ended in Jun. 2024 was $575.3 Mil. China Shineway Pharmaceutical Group's annualized Debt-to-Revenue for the quarter that ended in Jun. 2024 was 0.08.


China Shineway Pharmaceutical Group Debt-to-Revenue Historical Data

The historical data trend for China Shineway Pharmaceutical Group's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

China Shineway Pharmaceutical Group Debt-to-Revenue Chart

China Shineway Pharmaceutical Group Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.15 0.15 0.01 - 0.07

China Shineway Pharmaceutical Group Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - 0.06 0.07 0.08

Competitive Comparison of China Shineway Pharmaceutical Group's Debt-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, China Shineway Pharmaceutical Group's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


China Shineway Pharmaceutical Group's Debt-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, China Shineway Pharmaceutical Group's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where China Shineway Pharmaceutical Group's Debt-to-Revenue falls into.



China Shineway Pharmaceutical Group Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

China Shineway Pharmaceutical Group's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(42.152 + 0.05) / 632.551
=0.07

China Shineway Pharmaceutical Group's annualized Debt-to-Revenue for the quarter that ended in Jun. 2024 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(46.684 + 1.706) / 575.268
=0.08

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is two times the quarterly (Jun. 2024) Revenue data.


China Shineway Pharmaceutical Group Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of China Shineway Pharmaceutical Group's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


China Shineway Pharmaceutical Group Business Description

Traded in Other Exchanges
Address
Luan Cheng, Hebei Province, Shijiazhuang, CHN
China Shineway Pharmaceutical Group Ltd is an investment holding company in the People's Republic of China. It is engaged in the research, development, manufacturing, and trading of modern Chinese medicines. The company's products comprise injection, soft capsule, granule, and others of which injection generates maximum revenue to the company.

China Shineway Pharmaceutical Group Headlines